NO973770L - Rask test for bestemmelse av mengden av funksjonelt inaktivt gen i et genterapi-vektor-preparat - Google Patents
Rask test for bestemmelse av mengden av funksjonelt inaktivt gen i et genterapi-vektor-preparatInfo
- Publication number
- NO973770L NO973770L NO973770A NO973770A NO973770L NO 973770 L NO973770 L NO 973770L NO 973770 A NO973770 A NO 973770A NO 973770 A NO973770 A NO 973770A NO 973770 L NO973770 L NO 973770L
- Authority
- NO
- Norway
- Prior art keywords
- vectors
- gene
- vector
- cells
- tumor
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 143
- 108090000623 proteins and genes Proteins 0.000 title claims description 54
- 238000012360 testing method Methods 0.000 title claims description 47
- 238000001415 gene therapy Methods 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title description 11
- 230000002950 deficient Effects 0.000 claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 34
- 210000004881 tumor cell Anatomy 0.000 claims description 30
- 239000012636 effector Substances 0.000 claims description 27
- 241000701161 unidentified adenovirus Species 0.000 claims description 20
- 239000013642 negative control Substances 0.000 claims description 17
- 239000013641 positive control Substances 0.000 claims description 12
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 9
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 9
- 108700025694 p53 Genes Proteins 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 108060001084 Luciferase Proteins 0.000 claims description 7
- 230000004565 tumor cell growth Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 238000003908 quality control method Methods 0.000 abstract description 6
- 238000003556 assay Methods 0.000 abstract description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 19
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 201000005202 lung cancer Diseases 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 108700020796 Oncogene Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 7
- 102000043276 Oncogene Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 241000212384 Bifora Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 241000920340 Pion Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000018855 positive regulation of programmed cell death Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/390,887 US5637456A (en) | 1995-02-17 | 1995-02-17 | Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation |
| PCT/US1996/002042 WO1996025515A1 (fr) | 1995-02-17 | 1996-02-14 | Test rapide de determination de la quantite de gene fonctionnellement inactif dans une preparation de vecteurs de therapie genique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO973770D0 NO973770D0 (no) | 1997-08-15 |
| NO973770L true NO973770L (no) | 1997-10-15 |
Family
ID=23544364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO973770A NO973770L (no) | 1995-02-17 | 1997-08-15 | Rask test for bestemmelse av mengden av funksjonelt inaktivt gen i et genterapi-vektor-preparat |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5637456A (fr) |
| EP (1) | EP0811077B1 (fr) |
| JP (1) | JPH11500012A (fr) |
| KR (1) | KR19980702312A (fr) |
| AT (1) | ATE283371T1 (fr) |
| AU (1) | AU700427B2 (fr) |
| BR (1) | BR9607613A (fr) |
| CA (1) | CA2213116A1 (fr) |
| CZ (1) | CZ257597A3 (fr) |
| DE (1) | DE69633913D1 (fr) |
| HU (1) | HUP9802062A3 (fr) |
| NO (1) | NO973770L (fr) |
| NZ (1) | NZ303040A (fr) |
| PL (1) | PL182817B1 (fr) |
| SK (1) | SK283027B6 (fr) |
| UA (1) | UA45492C2 (fr) |
| WO (1) | WO1996025515A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2760009A1 (fr) * | 1997-02-27 | 1998-08-28 | Atochem Elf Sa | Procede de fabrication d'acide acrylique a partir de l'acroleine par reaction redox et l'utilisation d'une composition solide d'oxydes mixtes comme systeme redox dans ladite reaction |
| US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| JP2004525070A (ja) * | 2000-07-19 | 2004-08-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 脳の神経変性疾患の治療法 |
| FR2821624B1 (fr) * | 2001-03-01 | 2004-01-02 | Sod Conseils Rech Applic | Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses |
| US6908560B2 (en) * | 2003-03-12 | 2005-06-21 | Basin Water, Inc. | Zero brine, zero rinse water process for treatment of contaminated drinking water for removal of arsenic |
| CN103113463B (zh) * | 2005-12-13 | 2015-02-18 | 国立大学法人京都大学 | 核重新编程因子 |
| US20090227032A1 (en) * | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US9213999B2 (en) * | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| JP5346925B2 (ja) | 2008-05-02 | 2013-11-20 | 国立大学法人京都大学 | 核初期化方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4975365A (en) * | 1987-05-12 | 1990-12-04 | The John Hopkins University | Assay for measuring DNA cell repair potential |
| US5212057A (en) * | 1988-10-26 | 1993-05-18 | University Of Florida | Biological system for constructing and testing viral vaccines |
| DE69233013T2 (de) * | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| FR2704234B1 (fr) * | 1993-04-22 | 1995-07-21 | Centre Nat Rech Scient | Virus recombinants, preparation et utilisation en therapie genique. |
| KR100356615B1 (ko) * | 1993-07-13 | 2003-04-03 | 아방티 파르마 소시에테 아노님 | 결함아데노바이러스벡터및유전자치료에서그의사용 |
-
1995
- 1995-02-17 US US08/390,887 patent/US5637456A/en not_active Expired - Fee Related
-
1996
- 1996-02-14 DE DE69633913T patent/DE69633913D1/de not_active Expired - Lifetime
- 1996-02-14 CZ CZ972575A patent/CZ257597A3/cs unknown
- 1996-02-14 AU AU49248/96A patent/AU700427B2/en not_active Ceased
- 1996-02-14 EP EP96905510A patent/EP0811077B1/fr not_active Expired - Lifetime
- 1996-02-14 UA UA97084262A patent/UA45492C2/uk unknown
- 1996-02-14 NZ NZ303040A patent/NZ303040A/en unknown
- 1996-02-14 AT AT96905510T patent/ATE283371T1/de not_active IP Right Cessation
- 1996-02-14 PL PL96321869A patent/PL182817B1/pl not_active IP Right Cessation
- 1996-02-14 CA CA002213116A patent/CA2213116A1/fr not_active Abandoned
- 1996-02-14 KR KR1019970705709A patent/KR19980702312A/ko not_active Application Discontinuation
- 1996-02-14 JP JP8525132A patent/JPH11500012A/ja active Pending
- 1996-02-14 SK SK1113-97A patent/SK283027B6/sk unknown
- 1996-02-14 HU HU9802062A patent/HUP9802062A3/hu unknown
- 1996-02-14 BR BR9607613-5A patent/BR9607613A/pt not_active Application Discontinuation
- 1996-02-14 WO PCT/US1996/002042 patent/WO1996025515A1/fr active IP Right Grant
-
1997
- 1997-08-15 NO NO973770A patent/NO973770L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0811077A1 (fr) | 1997-12-10 |
| AU700427B2 (en) | 1999-01-07 |
| JPH11500012A (ja) | 1999-01-06 |
| WO1996025515A1 (fr) | 1996-08-22 |
| HUP9802062A2 (hu) | 1998-12-28 |
| PL321869A1 (en) | 1997-12-22 |
| NZ303040A (en) | 1998-07-28 |
| DE69633913D1 (de) | 2004-12-30 |
| KR19980702312A (ko) | 1998-07-15 |
| SK111397A3 (en) | 1998-04-08 |
| NO973770D0 (no) | 1997-08-15 |
| AU4924896A (en) | 1996-09-04 |
| EP0811077B1 (fr) | 2004-11-24 |
| CZ257597A3 (cs) | 1998-04-15 |
| UA45492C2 (uk) | 2002-04-15 |
| ATE283371T1 (de) | 2004-12-15 |
| BR9607613A (pt) | 1999-11-30 |
| CA2213116A1 (fr) | 1996-08-22 |
| SK283027B6 (sk) | 2003-02-04 |
| HUP9802062A3 (en) | 2001-08-28 |
| US5637456A (en) | 1997-06-10 |
| PL182817B1 (pl) | 2002-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | SFRPs are biphasic modulators of Wnt-signaling-elicited cancer stem cell properties beyond extracellular control | |
| Nagarajan et al. | EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression | |
| Buehler et al. | Host signaling and EGR1 transcriptional control of human cytomegalovirus replication and latency | |
| Spector | Activation and regulation of human cytomegalovirus early genes | |
| Li et al. | CHK1 inhibitor blocks phosphorylation of FAM122A and promotes replication stress | |
| CN107384922A (zh) | CRISPR/Cas9靶向敲除人CNE9基因及其特异性gRNA | |
| CN109952310A (zh) | 保护免受亲本病毒Georgia 2007分离株攻击的合理开发的非洲猪瘟减毒病毒毒株 | |
| MX2010008168A (es) | Biomarcadores p53. | |
| Meng et al. | C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1 | |
| NO973770L (no) | Rask test for bestemmelse av mengden av funksjonelt inaktivt gen i et genterapi-vektor-preparat | |
| Ignatoski et al. | Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer | |
| Zhou et al. | Orf virus ORF120 protein positively regulates the NF-κB pathway by interacting with G3BP1 | |
| Liao et al. | Marek’s disease virus US3 protein kinase phosphorylates chicken HDAC 1 and 2 and regulates viral replication and pathogenesis | |
| Ohashi et al. | Epstein-Barr virus nuclear antigen 3C (EBNA3C) interacts with the metabolism sensing C-terminal binding protein (CtBP) repressor to upregulate host genes | |
| Turner et al. | Human infectivity trait in Trypanosoma brucei: stability, heritability and relationship to sra expression | |
| Upton et al. | Evidence for CDK-dependent and CDK-independent functions of the murine gammaherpesvirus 68 v-cyclin | |
| Zhang et al. | Identification of functional domains within the bICP0 protein encoded by bovine herpesvirus 1 | |
| Listiana-Kriswandini et al. | Detection of Candida albicans biofilm proteins induced by glucose, lactose, soy protein, and iron | |
| Qian et al. | Polyoma virus middle T and small t antigens cooperate to antagonize p53-induced cell cycle arrest and apoptosis | |
| Lu et al. | Identification and characterization of a novel isoform of hepatopoietin | |
| Beucher et al. | Elevated radiation-induced γH2AX foci in G2 phase heterozygous BRCA2 fibroblasts | |
| Cai et al. | Down-regulation of transcription of the proapoptotic gene BNip3 in cultured astrocytes by murine coronavirus infection | |
| Dai et al. | Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients | |
| US20120015374A1 (en) | Enigma-mdm2 interaction and uses thereof | |
| Dulhanty et al. | Complementation of the DNA-repair defect in a CHO mutant by human DNA that lacks highly abundant repetitive sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |